Last reviewed · How we verify
14C-Quizartinib solution for infusion
14C-Quizartinib solution for infusion is a Small molecule drug developed by Daiichi Sankyo. It is currently in Phase 1 development.
At a glance
| Generic name | 14C-Quizartinib solution for infusion |
|---|---|
| Sponsor | Daiichi Sankyo |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Cerumen impaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14C-Quizartinib solution for infusion CI brief — competitive landscape report
- 14C-Quizartinib solution for infusion updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI
Frequently asked questions about 14C-Quizartinib solution for infusion
What is 14C-Quizartinib solution for infusion?
14C-Quizartinib solution for infusion is a Small molecule drug developed by Daiichi Sankyo.
Who makes 14C-Quizartinib solution for infusion?
14C-Quizartinib solution for infusion is developed by Daiichi Sankyo (see full Daiichi Sankyo pipeline at /company/daiichi-sankyo).
What development phase is 14C-Quizartinib solution for infusion in?
14C-Quizartinib solution for infusion is in Phase 1.
What are the side effects of 14C-Quizartinib solution for infusion?
Common side effects of 14C-Quizartinib solution for infusion include Cerumen impaction.